OUR IMPACT
AAHI collaborates with partners around the world to develop affordable and temperature stable vaccines and immunotherapies that can be made equitably accessible in areas most burdened by disease.
Stay tuned to learn more about how AAHI's immune-enhancing platform technologies are being used to address unmet needs.
TUBERCULOSIS
AAHI is developing a temperature stable, single-vial Tuberculosis vaccine candidate in human clinical trials. Tuberculosis is a leading infectious killer that infects 1.9 billion people (25% of the global population) and claims the lives of over 1.5 million people every year.
NEGLECTED TROPICAL DISEASES
Caused by a variety of pathogens, NTDs affect areas of extreme poverty. AAHI supports development of cost-effective products that can be efficiently distributed to rural and remote communities of Asia, Africa, and Latin America.
AMEBIASIS
AAHI is developing the first-ever amebiasis vaccine, administered as a nasal spray to induce a mucosal immune response that may provide enhanced protection against the disease-causing parasites, which reside in the intestines.
SNAKEBITE ENVENOMING
Antivenom to treat poisonous snake bite is in extremely limited supply. AAHI's adjuvant formulations support more efficient production of the antibodies that neutralize snake venom, thus reducing costs and helping to make life-saving antivenom more widely available.
MALARIA
AAHI collaborates with researchers around the world to incorporate adjuvant formulations with malaria proteins to target one of the most difficult, rapidly mutating, parasites that infects over 200 million people. Climate change is making it vastly more difficult to protect oneself from infected mosquitoes, as their behaviors begin to change in response to the changing environment.
